Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome.

F S Rep · 2023 · PMC10310940 · PMID 37398623

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In both human and nonhuman studies, elagolix has demonstrated a virtually immediate, dose-dependent, and highly significant reduction in LH and sex steroid levels ( 14 , 15 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.